trastuzumab for gastric cancer

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
trastuzumab for gastric cancer	1.34	0.5	9088	44	30
trastuzumab	1.39	0.5	473	27	11
for	1.68	0.5	6862	65	3
gastric	1.81	0.9	8044	56	7
cancer	1.37	0.3	3567	27	6

Keyword	CPC	PCC	Volume	Score
trastuzumab for gastric cancer	0.69	0.3	9156	38
trastuzumab deruxtecan gastric cancer	1.57	0.1	802	73
trastuzumab pembrolizumab gastric cancer	1.79	0.4	9577	80
trastuzumab gastric cancer fda approval	0.23	0.7	1246	71
folfox trastuzumab gastric cancer	0.01	0.7	8166	31
nivolumab trastuzumab gastric cancer	1.73	0.1	2199	60
trastuzumab deruxtecan gastric cancer ema	0.65	0.7	5616	78
trastuzumab deruxtecan colorectal cancer	0.12	0.8	4058	81
trastuzumab deruxtecan breast cancer	1.03	0.8	6552	32
trastuzumab deruxtecan lung cancer	0.86	0.7	5002	95
trastuzumab deruxtecan patient information	0.91	0.8	6027	56
trastuzumab deruxtecan urothelial carcinoma	0.96	0.2	3763	93
trastuzumab deruxtecan uterine cancer	0.11	0.4	7487	94
is trastuzumab deruxtecan chemotherapy	0.08	0.8	2187	96
trastuzumab vs trastuzumab deruxtecan	1.72	0.7	3144	20
trastuzumab deruxtecan clinical trial summary	0.97	0.8	513	65
trastuzumab deruxtecan fiche patient	0.29	1	7447	6
trastuzumab deruxtecan for injection	0.15	1	5849	6
trastuzumab deruxtecan fda approval	1.52	0.5	9574	46
trastuzumab deruxtecan in previously treated	1.84	0.7	4398	38
trastuzumab-deruxtecan	1.22	0.7	7078	42
development of trastuzumab deruxtecan	1.63	0.6	1245	62
trastuzumab deruxtecan fda package insert	1.28	0.2	7121	33
trastuzumab deruxtecan drug class	1.74	0.7	2708	17
trastuzumab deruxtecan brain metastases	0.09	0.7	5757	15